Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FDA018-ADC in advanced solid tumors
NCT05174637Phase 1Active, not recruiting
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- Oct 2021
- Primary completion
- Dec 2029
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of FDA018-ADC in triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), urothelial carcinoma (UC) and 6 more (7 arms), sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Primary endpoints: Dose Limiting Toxicity at 35 days, Maximum Tolerated Dose at 35 days and 3 more. Started Oct 2021; status: active, not recruiting.
02
Drugs
FDA018-ADC
03
Conditions
triple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)urothelial carcinoma (UC)small cell lung cancer (SCLC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05174637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05174637.